Mamatha Pasnoor, MD
Neurology · Kansas City, KSNPI 1437352820
Payments from drug & device makers
Across 763 payments — averaging $5122.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2.4M
- Argenx US, Inc.$765K
- Sanofi US Services Inc.$237K
- Takeda Pharmaceuticals U.S.A., Inc.$135K
- Catalyst Pharmaceuticals, Inc.$77K
- Amgen$67K
- plus $183K from 18 others
Across 14 payments — averaging $328.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$3K
- Lexicon Pharmaceuticals, Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 195 | $2,443,392 |
| Argenx US, Inc. | 332 | $764,684 |
| Sanofi US Services Inc. | 47 | $237,277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 88 | $135,135 |
| Catalyst Pharmaceuticals, Inc. | 15 | $77,497 |
| Amgen(2 entities) | 11 | $67,366 |
| Janssen Research & Development, LLC | 16 | $53,400 |
| UCB SA | 5 | $34,490 |
| Genentech, Inc. | 1 | $25,552 |
| Sanofi | 1 | $18,800 |
| Vertex | 1 | $14,734 |
| Grifols USA, LLC | 5 | $9,949 |
| Janssen Global Services, LLC | 13 | $9,306 |
| Grifols Therapeutics LLC | 1 | $6,922 |
| AstraZeneca(2 entities) | 10 | $3,951 |
| Lexicon Pharmaceuticals, Inc. | 2 | $2,529 |
| Janssen Scientific Affairs, LLC | 1 | $2,250 |
| Octapharma USA, Inc. | 1 | $1,000 |
| Hospira, Inc. | 11 | $180 |
| Johnson & Johnson | 1 | $99 |
| Alnylam Pharmaceuticals Inc. | 2 | $31 |
| Bio Products Laboratory USA, Inc. | 2 | $30 |
| GRT US Holding, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$3,908,604 in reported general payments places this provider in the 95th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Kansas City
- Ivan OsorioKansas City$101.7M
- Sharon LynchKansas City$9.3M
- Jeffrey BurnsKansas City$6.2M
- Rajesh PahwaKansas City$5M
- Constantine FarmakidisKansas City$649K
- Richard DubinskyKansas City$261K
- Patrick LandazuriKansas City$256K
- Michael AbrahamKansas City$203K
- Omar JawdatKansas City$111K
- Amanda ThuringerKansas City$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.